Some Asian Nations Reforming Drug Policies; China Unlikely to Curb Fentanyl Exports in Short Term
May 15, 2019
This report highlights the shifting drug policy landscape in Asia, with a special focus on (1) the violent crackdown on drug users and sellers in the Philippines, (2) Thailand's move toward an alternative approach of reducing criminal sanctions for drug use and improving access to medication treatment and needle exchange, and (3) China's emergence as a major source of many new chemical precursors and drugs that are exported outside Asia.
Insights and Opportunities for Change
|PDF file||1.6 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
|Add to Cart||Paperback118 pages||$31.00||$24.80 20% Web Discount|
Changing patterns in drug use and supply can affect the well-being and development of Asian countries in many ways: The burden of disease from injection drug use, overreliance on the criminal justice system, and rise of drug-related crime can impede economic, environmental, and social development. Historically, countries in Asia have addressed illicit drug use and supply with harsh punishments, including compulsory treatment and the death penalty. The region has long espoused the goal of creating a drug-free society, a goal that has been abandoned in other parts of the globe for being infeasible.
This report describes the illicit drug policy landscape for the Association of Southeast Asian Nations (ASEAN) + 3 countries (China, Japan, and South Korea), which account for about 30 percent of the world's population. The authors also present three case studies on the shifting drug policy landscape in Asia: (1) the violent crackdown on people who use or sell drugs in the Philippines, (2) Thailand's move from a similar crackdown toward an alternative approach of reducing criminal sanctions for drug use and improving access to medication treatment and needle exchange, and (3) China's emergence as a major source of many new chemical precursors and drugs, like fentanyl, that are exported outside Asia.
Drug Use and Drug-Related Disease
Drug and Precursor Chemical Production
Drug Policies in Asia
Recommendations for Improving Research and Policies in the Region
This project is a RAND Venture. Funding was provided by gifts from RAND supporters and income from operations. The research was conducted by the RAND Center for Asia Pacific Policy (CAPP) within International Programs.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.